(Q35917125)

11 August 2017

1 reference

title

Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections (English)

1 reference

11 August 2017

Eric De Clercq

1

1 reference

11 August 2017

publication date

1 June 2003

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

1

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

21-43

1 reference

Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Parapoxviruses are strongly inhibited in vitro by cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Cidofovir in the treatment of poxvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Successful treatment of recalcitrant condyloma with topical cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Local treatment of HPV-induced skin lesions by Cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Adefovir nephrotoxicity and mitochondrial DNA depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.1.21

21 January 2018

Identifiers

DOI

10.1586/14787210.1.1.21

1 reference

11 August 2017

1 reference